Successful Retreatment with Elotuzumab for Multiple Myeloma with Extramedullary Relapse while Being Treated with Lenalidomide and Dexamethasone

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Blade J, Cibeira MT, Rosinol L, de Larrea CF (2009) Extramedullary Myeloma Blood 114:SCI–SC5

    Google Scholar 

  2. 2.

    Descamps G, Pellat-Deceunynck C, Szpak Y, Bataille R, Robillard N, Amiot M (2004) The magnitude of Akt/phosphatidylinositol 3'-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J Immunol 173:4953–4959

    CAS  Article  Google Scholar 

  3. 3.

    Guo H, Cruz-Munoz ME, Wu N, Robbins M, Veillette A (2015) Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells. Mol Cell Biol 35:41–51

    Article  Google Scholar 

  4. 4.

    Kumar SK, Callander NS, Alsina M, et al (2018) NCCN Guidelines Insights; Multiple Myeloma, Version 3.2018. J Natl Compr Canc Netw 16:11–20

  5. 5.

    Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O’Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P (2016) Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 375:1319–1331

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Satoko Oka.

Ethics declarations

Satoko Oka declares that she has no conflicts of interest in the present study.

Kazuo Ono declares that he has no conflicts of interest in the present study.

Masaharu Nohgawa declares that he has no conflicts of interest in the present study.

This article does not contain any studies with human participants performed by any of the authors.

This patient provided his written informed consent to receive each regimen, and treatment was administered according to the principles of the Declaration of Helsinki and this study was approved by the institutional ethics committee.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Oka, S., Ono, K. & Nohgawa, M. Successful Retreatment with Elotuzumab for Multiple Myeloma with Extramedullary Relapse while Being Treated with Lenalidomide and Dexamethasone. Pathol. Oncol. Res. 26, 1993–1995 (2020). https://doi.org/10.1007/s12253-019-00725-x

Download citation